Gastroenterology
Browse by
Research outputs from the Gastroenterology department at the RD&E.
Recent Submissions
-
Association between level of fecal calprotectin and progression of Crohn's Disease
(Elsevier, 2019-02-14)Mucosal healing is associated with improved outcomes in patients with Crohn’s disease (CD), but assessment typically requires ileocolonoscopy. Calprotectin can be measured in fecal samples to determine luminal disease ... -
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
(Elsevier, 2019-05)Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors that predict primary non-response at week 14 after ... -
Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease
(JAMA, 2019-02)Use of thiopurines may be limited by myelosuppression. TPMT pharmacogenetic testing identifies only 25% of at-risk patients of European ancestry. Among patients of East Asian ancestry, NUDT15 variants are associated with ... -
Inflammatory bowel disease in children and adolescents.
(Canadian Medical Association, 2019-02-11) -
Systematic review of definitions and outcome measures for return of bowel function after gastrointestinal surgery.
(Wiley, 2018-10)Ileus is common after gastrointestinal surgery and has been identified as a research priority. Several issues have limited previous research, including a widely accepted definition and agreed outcome measure. This review ... -
Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
(Taylor & Francis, 2018-10-24)We aimed to understand the way in which therapeutic drug monitoring (TDM) is used, understood and interpreted for anti-TNF agents in IBD. -
Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT
(NIHR, 2018-06)Protein biomarkers with associations with the activity and outcomes of diseases are being identified by modern proteomic technologies. They may be simple, accessible, cheap and safe tests that can inform diagnosis, prognosis, ... -
Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population.
(PLoS, 2018-05)As part of a broader collaborative network of exome sequencing studies, we developed a jointly called data set of 5,685 Ashkenazi Jewish exomes. We make publicly available a resource of site and allele frequencies, which ... -
Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.
(Wiley, 2018-04)Primary care faecal calprotectin testing distinguishes inflammatory bowel disease (IBD) from functional gut disorder in young patients presenting with abdominal symptoms; however, previous evaluations have excluded patients ... -
The Impact of NOD2 Variants on Fecal Microbiota in Crohn’s Disease and Controls Without Gastrointestinal Disease
(Oxford Academic, 2018-03) -
The Royal Free Hospital 'hub-and-spoke network model' delivers effective care and increased access to liver transplantation.
(Elsevier, 2018-01)'Hub-and-spoke' networks may be one solution to reduce the geographical inequality in access to liver transplantation (LT) and the growing demands on, and saturation of, LT centres. It is not clear if such networks improve ... -
Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
(Oxford Academic, 2017-12)Virtual biologics clinics are often used to review patients with inflammatory bowel disease receiving biological therapy, with decisions whether to continue, switch, or stop therapy made based on review of symptoms, disease ... -
A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn’s disease following surgical resection (TOPPIC)
(NIHR, 2017-09)Crohn’s disease (CD) is a chronic, relapsing, inflammatory bowel disease. Up to 65% of patients with CD require an operation to control the disease within 10 years. Both endoscopic and clinical recurrence is common within ... -
Non selective beta blockers in cirrhosis.
(Elsevier, 2017-08-05) -
Interaction Between NOD2 and Smoking in the Pathogenesis of Crohn's Disease.
(Elsevier, 2017-07) -
Editorial: which iron preparation for patients with IBD?
(Wiley, 2017-07)
RSS 1.0